Literature DB >> 18805656

Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Douglas M Ziedonis1, Leslie Amass, Marc Steinberg, George Woody, Jonathan Krejci, Jeffrey J Annon, Allan J Cohen, Nancy Waite-O'Brien, Susan M Stine, Dennis McCarty, Malcolm S Reid, Lawrence S Brown, Robert Maslansky, Theresa Winhusen, Dean Babcock, Greg Brigham, Joan Muir, Deborah Orr, Betty J Buchan, Terry Horton, Walter Ling.   

Abstract

Few studies in community settings have evaluated predictors, mediators, and moderators of treatment success for medically supervised opioid withdrawal treatment. This report presents new findings about these factors from a study of 344 opioid-dependent men and women prospectively randomized to either buprenorphine-naloxone or clonidine in an open-label 13-day medically supervised withdrawal study. Subjects were either inpatient or outpatient in community treatment settings; however not randomized by treatment setting. Medication type (buprenorphine-naloxone versus clonidine) was the single best predictor of treatment retention and treatment success, regardless of treatment setting. Compared to the outpatient setting, the inpatient setting was associated with higher abstinence rates but similar retention rates when adjusting for medication type. Early opioid withdrawal severity mediated the relationship between medication type and treatment outcome with buprenorphine-naloxone being superior to clonidine at relieving early withdrawal symptoms. Inpatient subjects on clonidine with lower withdrawal scores at baseline did better than those with higher withdrawal scores; inpatient subjects receiving buprenorphine-naloxone did better with higher withdrawal scores at baseline than those with lower withdrawal scores. No relationship was found between treatment outcome and age, gender, race, education, employment, marital status, legal problems, baseline depression, or length/severity of drug use. Tobacco use was associated with worse opioid treatment outcomes. Severe baseline anxiety symptoms doubled treatment success. Medication type (buprenorphine-naloxone) was the most important predictor of positive outcome; however the paper also considers other clinical and policy implications of other results, including that inpatient setting predicted better outcomes and moderated medication outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18805656      PMCID: PMC2770269          DOI: 10.1016/j.drugalcdep.2008.06.016

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  32 in total

1.  Smoking status and substance abuse severity in a residential treatment sample.

Authors:  Jonathan Krejci; Marc L Steinberg; Douglas Ziedonis
Journal:  Drug Alcohol Depend       Date:  2003-12-11       Impact factor: 4.492

2.  [Is premature termination of opiate detoxification due to intensive withdrawal or craving?].

Authors:  N Scherbaum; K Heppekausen; F Rist
Journal:  Fortschr Neurol Psychiatr       Date:  2004-01       Impact factor: 0.752

3.  The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations.

Authors:  R M Baron; D A Kenny
Journal:  J Pers Soc Psychol       Date:  1986-12

4.  Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine- and methadone-assisted withdrawal.

Authors:  B J Rounsaville; T Kosten; H Kleber
Journal:  J Nerv Ment Dis       Date:  1985-02       Impact factor: 2.254

Review 5.  Clonidine and the treatment of the opiate withdrawal syndrome.

Authors:  M Gossop
Journal:  Drug Alcohol Depend       Date:  1988-07       Impact factor: 4.492

6.  Predicting completion of outpatient opioid detoxification with clonidine.

Authors:  Stephen Strobbe; Kirk J Brower; Luke W Galen
Journal:  Am J Addict       Date:  2003 May-Jun

7.  Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Authors:  Leslie Amass; Walter Ling; Thomas E Freese; Chris Reiber; Jeffrey J Annon; Allan J Cohen; Dennis McCarty; Malcolm S Reid; Lawrence S Brown; Cynthia Clark; Douglas M Ziedonis; Jonathan Krejci; Susan Stine; Theresa Winhusen; Greg Brigham; Dean Babcock; Joan A Muir; Betty J Buchan; Terry Horton
Journal:  Am J Addict       Date:  2004

8.  A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts.

Authors:  W K Bickel; M L Stitzer; G E Bigelow; I A Liebson; D R Jasinski; R E Johnson
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

Review 9.  The Clinical Opiate Withdrawal Scale (COWS).

Authors:  Donald R Wesson; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2003 Apr-Jun

10.  Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.

Authors:  W K Bickel; M L Stitzer; G E Bigelow; I A Liebson; D R Jasinski; R E Johnson
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

View more
  25 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

2.  Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Authors:  Jermaine D Jones; Rachel R Luba; Jonathan L Vogelman; Sandra D Comer
Journal:  Am J Addict       Date:  2015-12-21

Review 3.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

4.  Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003.

Authors:  Celestina Barbosa-Leiker; Sterling McPherson; Mary Rose Mamey; G Leonard Burns; Matthew E Layton; John Roll; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2015-04-11       Impact factor: 4.492

5.  A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

Authors:  Traci R Rieckmann; Anne E Kovas; Bentson H McFarland; Amanda J Abraham
Journal:  J Subst Abuse Treat       Date:  2011-08-06

6.  Predictors of buprenorphine treatment success of opioid dependence in two Baltimore City grassroots recovery programs.

Authors:  April Joy Damian; Tamar Mendelson; Deborah Agus
Journal:  Addict Behav       Date:  2017-05-10       Impact factor: 3.913

7.  Smoking and opioid detoxification: behavioral changes and response to treatment.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; David A Gorelick
Journal:  Nicotine Tob Res       Date:  2013-04-09       Impact factor: 4.244

8.  Implementations of a text-message intervention to increase linkage from the emergency department to outpatient treatment for substance use disorders.

Authors:  Julie Kmiec; Brian Suffoletto
Journal:  J Subst Abuse Treat       Date:  2019-02-21

9.  Progression to regular heroin use: examination of patterns, predictors, and consequences.

Authors:  Eric A Woodcock; Leslie H Lundahl; Jonathan J K Stoltman; Mark K Greenwald
Journal:  Addict Behav       Date:  2015-02-26       Impact factor: 3.913

10.  Gender differences in a clinical trial for prescription opioid dependence.

Authors:  R Kathryn McHugh; Elise E Devito; Dorian Dodd; Kathleen M Carroll; Jennifer Sharpe Potter; Shelly F Greenfield; Hilary Smith Connery; Roger D Weiss
Journal:  J Subst Abuse Treat       Date:  2013-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.